[A25-75] Guselkumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2025
Project no.:
A25-75
Commission:
Commission awarded on 01.06.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): hint of minor added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-75
| Project no. | Title | Status |
|---|---|---|
| A20-112 | Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-60 | Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-74 | Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |